Everything below concerns 肠促胰素. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Soybean seed contains 18–19% oil. To extract soybean oil from seed, the soybeans are cracked, adjusted for moisture content, rolled into flakes, and solvent-extracted with commercial hexane. The oil is then refined, blended for different applications, and sometimes hydrogenated. Soybean oils, both liquid and partially hydrogenated, are exported abroad, sold as "vegetable oil", or end up in a wide variety of processed foods. As of 2022, China produces 29% of the world's soybean oil and the United States is the second largest producer at 21%.
The vulva has a major role to play in the reproductive system. It provides entry to, and protection for the uterus, and the right conditions in terms of warmth and moisture that aids in its sexual and reproductive functions. The vulva is richly innervated and provides pleasure when properly stimulated. The mons pubis provides cushioning against the pubic bone during intercourse. A number of different secretions are associated with the vulva, including urine (from the urethral opening during urination through control of the external sphincter muscle), sweat (from the apocrine glands), menses (leaving from the vagina via the introitus), sebum (from the sebaceous glands), alkaline fluid (from the Bartholin's glands), mucus (from the Skene's glands), vaginal lubrication from the vaginal wall and smegma. Smegma is a white substance formed from a combination of dead cells, skin oils, moisture and naturally occurring bacteria, that forms in the genitalia. In females, this thickened secretion collects around the clitoris and labial folds. It can cause discomfort during sexual activity as it can cause the clitoral glans to stick to the hood, and is easily removed by bathing. Aliphatic acids known as copulins are also secreted in the vagina. These are believed to act as pheromones. Their fatty acid composition, and consequently their odor changes in relation to the stages of the menstrual cycle.
== Legacy == Following the dissolution of the Selous Scouts in 1980, most of its white soldiers emigrated to South Africa and were integrated into the South African Special Forces and the South African Police's special units. This formed part of an effort by the SADF to recruit white veterans of Rhodesian counter-insurgency units that was designated Operation Winter. Reid-Daly was among the Selous Scouts who moved to South Africa, and was appointed the head of Transkei Defence Force (the military of the nominally independent 'bantustan' of Transkei) in the early 1980s. He recruited other former Selous Scouts to train the force, but was forced to resign in 1987 after Transkei's rulers were overthrown by a military officer who had previously been trained by the Selous Scouts. The former Selous Scouts contributed to the adoption by the South African security forces of the unit's ruthless tactics. For instance, former Selous Scouts comprised most of the initial personnel of the South African Koevoet unit, and it used similar tactics. This unit was responsible for many human rights violations. The South African Police's Vlakplaas paramilitary hit squad that was established in 1979 was also inspired by the Selous Scouts, as was the Civil Cooperation Bureau that was formed in 1986. Following the end of the Apartheid regime in South Africa some former Selous Scouts joined private military companies. Reid-Daly's memoirs Selous Scouts: Top Secret War, which were first published in 1982, have had a strong influence on the historiography of the Rhodesian Bush War.
Selenium is a chemical element; it has symbol Se and atomic number 34. It has various physical appearances, including a brick-red powder, a vitreous black solid, and a grey metallic-looking form. It seldom occurs in this elemental state or as pure ore compounds in Earth's crust. Selenium (from σελήνη 'moon') was discovered in 1817 by Jöns Jacob Berzelius, who noted the similarity of the new element to the previously discovered tellurium (named for the Earth). Selenium is found in metal sulfide ores, where it substitutes for sulfur. Commercially, selenium is produced as a byproduct in the refining of these ores. Minerals that are pure selenide or selenate compounds are rare. The chief commercial uses for selenium today are glassmaking and pigments. Selenium is a semiconductor and is used in photocells. Applications in electronics, once important, have been mostly replaced with silicon semiconductor devices. Selenium is still used in a few types of DC power surge protectors and one type of fluorescent quantum dot. Although trace amounts of selenium are necessary for cellular function in many animals, including humans, both elemental selenium and (especially) selenium salts are toxic in even small doses, causing selenosis. Symptoms include (in decreasing order of frequency): diarrhea, fatigue, hair loss, joint pain, nail brittleness or discoloration, nausea, headache, tingling, vomiting, and fever.
Sources: en.wikipedia.org
VIP neurons located in the hypothalamus, specifically the dorsal anterior hypothalamus and ventromedial hypothalamus, have an effect on social behaviors in many species of vertebrates. Studies in birds suggest that VIP circuits may play an important role in regulating a wide range of social behaviors. This social circuit includes many areas of the hypothalamus along with the amygdala and the ventral tegmental area. The production and release of the neuropeptide VIP is centralized in the hypothalamic and extrahypothalamic regions of the brain and from there it is able to modulate the release of prolactin secretion. Once secreted from the pituitary gland, prolactin can increase many behaviors such as parental care and aggression. In certain species of birds with a knockout VIP gene there was an observable decrease in overall aggression over nesting territory.
== History == Myelofibrosis was first described in 1879 by Gustav Heuck. Eponyms for the disease are Heuck-Assmann disease or Assmann's Disease, for Herbert Assmann, who published a description under the term "osteosclerosis" in 1907. It was characterised as a myeloproliferative condition in 1951 by William Dameshek. The disease was also known as myelofibrosis with myeloid metaplasia and agnogenic myeloid metaplasia The World Health Organization utilized the name chronic idiopathic myelofibrosis until 2008, when it adopted the name of primary myelofibrosis. In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a distinct clinical entity from overt PMF.
=== Brand names === It is marketed under the brand name Rivotril by Roche in Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Estonia, Germany, Hungary, Iceland, Ireland, Italy, China, Mexico, the Netherlands, Norway, Portugal, Peru, Pakistan, Romania, Serbia, South Africa, South Korea, Saudi Arabia, Spain, Turkey, and the United States; Emcloz, Linotril, Lonazep, Clotrin and Clonotril in India and other parts of Europe; under the name Riklona in Indonesia and Malaysia; and under the brand name Klonopin by Roche in the United States. Other names, such as Antelepsin, Clonoten, Ravotril, Rivotril, Iktorivil, Clonex (Israel), Paxam, Petril, Naze, Zilepam and Kriadex, are used throughout the world. In August 2021, Roche Australia transferred Rivotril to Pharmaco Australia Ltd.
=== Legal status === Zanidatamab was approved for medical use in the United States in November 2024. In April 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ziihera, intended for the treatment of adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer. The applicant for this medicinal product is Jazz Pharmaceuticals Ireland Limited. Zanidatamab was authorized for medical use in the European Union in June 2025.
The journalist and diplomat José Rodríguez Elizondo maintained that from that moment on, a relationship with Peru was consolidated in Chile, inspired by mistrust and prejudice, where the Chileanization carried out by the Patriotic Leagues would be the definitive establishment of mass nationalism, almost Chilean chauvinism, which "led to exalt xenophobic features, fundamentally anti-Peruvian". This perspective, with its nuances, became accessible to many sectors beyond Tarapacá, such as the embarrassing event of Don Ladislao's War, in which accuse of "sold out Peruvian gold" anyone who questioned the action of Minister of War, Ladislao Errázuriz, of mobilizing troops from Santiago to the north, in a farce to attack a fictitious Peruvian enemy, while in reality he wanted the army away from the capital (due to its proximity to the candidate Arturo Alessandri Palma). In addition, innumerable newspapers, starting with the newspapers and magazines of the mainstream press (El Mercurio, El Diario Ilustrado, El Chileno, Zig-Zag and Sucesos), shared a similar idea of the conception of the homeland. In Congress, this thought full of Peruvian-phobic prejudices was personified by the Balmacedista deputy, Anselmo Blanlot, who would end up propagating the idea that the anti-Peruvian violence in the north was truly "imaginary attacks." Peru was seen as barbarism and Chile, it was supposed, light and civilization. Other politicians with anti-Peruvian tendencies were Agustín Edwards Mac-Clure, Víctor Eastman Cox or Rafael Edwards Salas.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.